# EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

> **NCT03618381** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Seattle Children's Hospital** · enrollment: 44 (estimated)

## Conditions studied

- Pediatric Solid Tumor
- Germ Cell Tumor
- Retinoblastoma
- Hepatoblastoma
- Wilms Tumor
- Rhabdoid Tumor
- Carcinoma
- Osteosarcoma
- Ewing Sarcoma
- Rhabdomyosarcoma
- Synovial Sarcoma
- Clear Cell Sarcoma
- Malignant Peripheral Nerve Sheath Tumors
- Desmoplastic Small Round Cell Tumor
- Soft Tissue Sarcoma
- Neuroblastoma

## Interventions

- **BIOLOGICAL:** second generation 4-1BBζ EGFR806-EGFRt
- **BIOLOGICAL:** second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG

## Key facts

- **NCT ID:** NCT03618381
- **Lead sponsor:** Seattle Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-18
- **Primary completion:** 2040-06
- **Final completion:** 2040-06
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03618381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03618381, "EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03618381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*